Quinoline derivatives which are 5-hydroxytryptamine antagonists
Patent 4607039 Issued on August 19, 1986. Estimated Expiration Date: 
August 19, 2003. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
August 19, 2003. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References Re16394 1572768 1860286 Imidazolyl alkylaminopyridone and pyridinethione compounds Octahydro-2H-pyrrolo[3,4-g]quinolines 9-Hydroxyoctahydrobenzo [C] quinolines and intermediates therefor Heterocyclic compounds Piperid-4-yl ureas and thio ureas used as anti-depressant agents Quinoline derivatives which are 5-hydroxytryptamine antagonists Patent #: 4435405 InventorsAssigneeApplicationNo. 06/488607 filed on 04/25/1983US Classes:514/312, Chalcogen attached directly to the six-membered hetero ring by nonionic bonding546/155, Plural chalcogens attached directly to the six-membered hetero ring by nonionic bonding546/157Chalcogen attached directly at 2-position by nonionic bondingExaminersPrimary: Daus, Donald G.Assistant: Rivers, Diana G. Attorney, Agent or FirmInternational ClassesC07D 409/00 (20060101)C07D 409/04 (20060101) C07D 215/18 (20060101) C07D 215/36 (20060101) C07D 215/00 (20060101) C07D 215/22 (20060101) C07D 215/227 (20060101) C07D 333/00 (20060101) C07D 333/24 (20060101) Foreign Application Priority Data1982-05-04 GBAbstractCompounds of the formula: ##STR1## wherein A stands for the radical --(CH2)2 -- which may optionally be substituted by one or two (1-2C)alkyl radicals; Q stands for an oxygen or sulphur atom; R° stands for a (1-4C)alkyl, (1-4C)alkoxy or cyclopropyl radical; R1 stands for a defined (3-4C)alkyl radical, a phenyl radical which may optionally bear a defined substituent, or a defined heteroaryl radical of 5 or 6 ring atoms; and R2 and R3 stand for hydrogen or a (1-2C)alkyl radical; and pharmaceutically-acceptable acid-addition salts thereof. Processes for the manufacture of said compounds. Pharmaceutical compositions comprising one of said compounds and a pharmaceutical diluent or carrier. The compounds are 5-hydroxytryptamine antagonists.Other References
|
| ||||||||||||||
